anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The project "Eye Tracking as a Predictor of Methylphenidate (MPH) Response in Low Functioning Autism Spectrum Disorders (ASD) with comorbid ADHD" will investigate the role of a non-invasive neurophysiological biomarker in an underserved population to clarify diagnosis and guide treatment decisions. Specifically, we will modify an existing eye tracking paradigm that discriminates between ADHD and typical youth, for use in an ASD cohort with (ASD+) and without an ADHD comorbidity. A case-control design (Aim 1) will lead into a randomized placebo controlled trial of MPH in children with ASD with comorbid ADHD (Aim 2). We hypothesize that children with ASD+ will demonstrate specific abnormalities in microsaccades, eye blink frequency, and pupil dilatation on continuous performance testing that will predict MPH treatment response on standardized clinical outcomes for ADHD. As a secondary measure, we will also perform a brief electrophysiological measure, short interval cortical inhibition (SICI), as measured by paired pulse transcranial magnetic stimulation (TMS). We have extensively investigated this measure as a robust predictor of ADHD diagnosis and symptom severity in ADHD and typical youth. We anticipate this personalized medicine-based approach to clarify ADHD co-occurrence in ASD will result in a novel neurophysiological biomarker will enhance diagnostic reliability and better match appropriate pharmacotherapy in a highly complex neurodevelopmental disease.
Patients receive oral vorinostat (SAHA) once a day on days 1-21. In both arms, treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
Prodn of natural colouring comprises solvent extn of the sub-soil parts of the Borraginaceae (Borage) family selected from Anchusa virginica, Lithospermum tinctorium, Onosma echiodides, Echuim rubrum and Alkanna tinctoria followed by concn of the solvent extract. The colorant is used in cosmetic hair dyeing compsn. Pref plants are Alkanna tinctoria and Onasma echioides and the pref pants are the bark of the roots. Solvents are pref 1-3C alcohols, 3-5C ketones, 1-2C halohydrocarbons and mixtures of these or a basic soln. The colourant is pref concentrated by liq/liq extn with a 1-2C halohydrcarbon. For the final concn, the soln is evaporated on a polyol, an animal or vegetable oil, or a surfactant. The compsn also pref contain a salt, esp of Al or Fe. The colourants are non-toxic, have anti-inflammatory and antibacterial properties, as well as having remarkable dyeing properties.
PURPOSE: Metabolic reprogramming in breast cancer (BC) subtypes offers potential personalized treatment targets. Estrogen receptor α (ERα)-positive BC patients undergoing endocrine therapy (ET) can develop ET-resistant metastatic disease. Specific mutations, like Y537S in ERα, drive uncontrolled cell proliferation. Targeting mutant receptor levels shows promise for inhibiting growth in metastatic BC expressing ERα variants. Additionally, metabolic reprogramming occurs in ERα Y537S mutant cells. Consequently, we conducted a screen to identify metabolic proteins reducing intracellular levels of ERα Y537S and inhibiting cell proliferation.
METHODS: Nine metabolic proteins were identified in a siRNA-based screen, with phosphomannose mutase 2 (PMM2) showing the most promise. We measured the impact of PMM2 depletion on ERα stability and cell proliferation in ERα Y537S mutant cells. Additionally, we tested the effect of PMM2 reduction on the hyperactive phenotype of the mutant and its proliferation when combined with metastatic BC treatment drugs.
RESULTS: PMM2 emerged as a significant target due to its correlation with better relapse-free survival, overexpression in ERα-positive tumors, and its elevation in ERα Y537S-expressing cells. Depletion of PMM2 induces degradation of ERα Y537S, inhibits cell proliferation, and reduces ERα signaling. Notably, reducing PMM2 levels re-sensitizes ERα Y537S-expressing cells to certain ET drugs and CDK4/CDK6 inhibitors. Mechanistically, depletion of PMM2 leads to a reduction in ESR1 mRNA levels, resulting in decreased ERα receptor protein expression. Furthermore, the reduction of PMM2 decreases FOXA1 levels, which plays a crucial role in ERα regulation.
CONCLUSIONS: Our findings establish PMM2 as an innovative therapeutic target for metastatic BC expressing the ERα Y537S variant, offering alternative strategies for managing and treating this disease.
The Spanish Familial Pancreatic Cancer Registry (PANGENFAM) was established in 2009 and aims to characterize the genotype and phenotype of familial pancreatic cancer (FPC). Furthermore, an early detection screening program for pancreatic ductal adenocarcinoma (PDAC) is provided to healthy high-risk individuals from FPC and hereditary pancreatic cancer families (first-degree relatives). This article describes our experience over the last 10 years in high-risk screening. Hereditary and familial pancreatic cancer families were identified through the oncology and gastroenterology units. High-risk individuals underwent annual screening with endoscopic ultrasound (EUS) and magnetic resonance (MRI) from age 40 or 10 years younger than the youngest affected family member. Results: PANGENFAM has enrolled 290 individuals from 143 families, including 52 PDAC cases and 238 high-risk individuals. All high-risk individuals eligible for screening were offered to enter the surveillance program, with 143 currently participating. Pancreatic abnormalities were detected in 94 individuals (median age 53 years (29-83), with common findings including cystic lesions and inhomogeneous parenchyma. Imaging test concordance was 66%. Surgical intervention was performed in 4 high-risk individuals following highly suspicious lesions detected by imaging. PANGENFAM is a valuable resource for science innovation, such as biobanking, with clinical and imaging data available for analysis. For high-risk families, it may offer a potential for early diagnosis. Collaboration with other national and international registries is needed to increase our understanding of the disease biology and to standardize criteria for inclusion and follow-up, optimizing cost-effectiveness and efficacy.
The present invention relates to a Chinese material medical preparation for clinically treating diseases, such as femoral head necrosis, bone fracture, lumbar protrusion, etc., which belongs to the technical field of a medicine. The present invention is characterized in that the present invention is prepared by using crude medicines in the following portions by weight: 480 to 500g of Chinese ephedra, 470 to 490g of notoginseng, 1300 to 1500g of curare, 490 to 510g of frankincense, 470 to 500g of myrrh, 180 to 200g of sanguis draconis, 230 to 250g of pawpaws and 240 to 260g of achyranthes roots. The Chinese ephedra, the notoginseng, the curare, the frankincense, the myrrh, the sanguis draconis, the pawpaws and the achyranthes roots are ground into 200 meshes of fine powder which is sieved, made into powdered traditional Chinese medicines and filled in capsules, or the fine powder is made into water-honeyed pills. The present invention which is the Chinese material medical preparation for treating the femoral head necrosis can be used for treating diseases, such as femoral head necrosis, particularly ischemic femoral head necrosis, etc. Various traditional Chinese medicines are adopted to optimize the formula, and thereby, the present invention can effectively treat diseases, such as femoral head necrosis, ischemic femoral head necrosis, bone fracture, lumbar protrusion, etc., in clinical treatment. The present invention has the characteristics of short treatment course, quick effect generation, low cost, no side effect and no relapse.
BACKGROUND: The epidemiology of psychogenic non-epileptic seizures (PNES) is still unclear. Although approximately 14 million people need neurosurgical care annually, there is a dearth of thorough analysis on PNES occurrence following surgery. This study seeks to estimate the proportion of newly diagnosed PNES.
METHODS: We conducted a literature search of the PubMed, Ovid, CINAHL, and Cochrane Library databases up to December 2023. We identified studies using an observational design on the occurrence of PNES in patients who underwent intracranial surgery, and confirmed diagnosis using video-EEG. Estimates are reported as proportions using random effects models. We reported both 95 % CIs and prediction intervals (PI). We assessed the risk of bias and identified the pooled odds ratio (OR) for mutually exclusive groups. The heterogeneity was investigated using the I² statistic and significance determined using Cochran's Q-test. Post-hoc Egger's regression test, and several sensitivity analyses were performed. This study was registered in PROSPERO (CRD42023488611).
RESULTS: Of the 1766 unique studies identified, 86 were selected for full-text review. Eight studies (n = 3,699) were eligible for inclusion. Studies, spanning from 1995 to 2017, primarily focused on epilepsy surgeries. The pooled proportion was 3 % (95 % CI 2 %-5 %; 95 % PI 0 %-11 %). Temporal resections indicated twofold increase of PNES comparing to either resections (OR 2.05, 95 %CI 0.81-5.19). The risk of bias assessment indicated satisfactory quality for included studies, and heterogeneity in estimates was mainly explained by publication year of studies and their rounded sample size.
CONCLUSIONS: Given the estimations, there is expected impact of intracranial procedures on functional seizures epidemiology. Further efforts need to understand the contribution of brain resections to PNES incidence.
Cardiac fibrosis is a major public health problem worldwide, with high morbidity and mortality, affecting almost all patients with heart disease worldwide. It is characterized by fibroblast activation, abnormal proliferation, excessive deposition, and abnormal distribution of extracellular matrix (ECM) proteins. The maladaptive process of cardiac fibrosis is complex and often involves multiple mechanisms. With the increasing research on cardiac fibrosis, redox has been recognized as an important part of cardiac remodeling, and an imbalance in redox homeostasis can adversely affect the function and structure of the heart. The metabolism of metal ions is essential for life, and abnormal metabolism of metal ions in cells can impair a variety of biochemical processes, especially redox. However, current research on metal ion metabolism is still very limited. This review comprehensively examines the effects of metal ion (iron, copper, calcium, and zinc) metabolism-mediated redox homeostasis on cardiac fibrosis, outlines possible therapeutic interventions, and addresses ongoing challenges in this rapidly evolving field.
Students in the control class received regular class instruction during the 5 weeks. This instruction did not deviate from regular instruction that was provided to all classes, including the intervention classes. During the intervention period, control group students completed the assessments once per week. The control class is considered a treatment-as-usual active control.
TARGRETIN induces substantial elevations in lipids in most patients. About 70% of patients with CTCL who received an initial dose of >300 mg/m2/day of TARGRETIN had fasting triglyceride levels greater than 2.5 times the upper limit of normal. About 55% had values over 800 mg/dL with a median of about 1200 mg/dL in those patients. Cholesterol elevations above 300 mg/dL occurred in approximately 60% and 75% of patients with CTCL who received an initial dose of 300 mg/m2/day or greater than 300 mg/m2/day, respectively. Decreases in high density lipoprotein (HDL) cholesterol to less than 25 mg/dL were seen in about 55% and 90% of patients receiving an initial dose of 300 mg/m2/day or greater than 300 mg/m2/day, respectively, of TARGRETIN. Monitor lipid changes and treat abnormalities during therapy. The effects on triglycerides, HDL cholesterol, and total cholesterol were reversible with cessation of therapy, and could generally be mitigated by dose reduction and/or concomitant antilipemic therapy.

Perform fasting blood lipid determinations before TARGRETIN therapy is initiated and weekly until the lipid response to TARGRETIN is established, which usually occurs within 2 to 4 weeks, and monitor at 8-week intervals thereafter. Fasting triglycerides should be normal or normalized with appropriate intervention prior to initiating TARGRETIN therapy. Maintain triglyceride levels below 400 mg/dL to reduce the risk of clinical sequelae [see Warnings and Precautions (5.2)]. If fasting triglycerides are elevated or become elevated during treatment, institute antilipemic therapy, and if necessary, reduce or interrupt the dose of TARGRETIN. In the 300 mg/m2/day initial dose group, 60% of patients were given lipid lowering drugs. Atorvastatin was used in 48% (73/152) of patients with CTCL. Because of a potential drug-drug interaction, avoid gemfibrozil use with TARGRETIN [see Drug Interactions (7)].
FIELD: medicine. SUBSTANCE: method involves applying aorticocoronary by-pass and plasmapheresis. Intravascular low intensity helium-neon laser therapy is concurrently applied. Nei-guan, Shao-hai and Tan-zhong biologically active points are to be exposed to millimetric bandwidth radio waves radiation. EFFECT: improved lipid metabolism and rheological blood properties; prolonged service life of autovenous by-pass. 2 dwg, 1 tbl
Visual assessment, while the primary method for pigmentation and erythema evaluation in clinical practice, is subjective, time-consuming, and may lead to variability in observations among clinicians. Objective and quantitative techniques are required for a precise evaluation of the disease's severity and the treatment's efficacy. This research examines the precision and utility of a newly developed skin imaging system in assessing pigmentation and erythema. Sixty participants were recruited, and their facial images were analyzed with the new OBSERV 520 x skin imaging system, compared to DERMACATCH for regional analysis and VISIA for full-face examination. The degree of skin pigmentation was clinically graded using the MASI scores evaluated by dermatologists. The data revealed positive correlations between the novel skin imaging system and the two conventional instruments in quantifying pigmentation and erythema, whether in regional or full-face analysis. Furthermore, the new skin imaging system positively correlated with the clinical MASI scores (r = 0.4314, P < 0.01). In contrast, our study found no significant correlation between the traditional system and clinical assessment, indicating a more substantial capacity for hyperpigmentation assessment in the new system. Our study validates the innovative skin imaging system's accuracy in evaluating pigmentation and erythema, demonstrating its feasibility for quantitative evaluation in both clinical and research purposes.
The present invention relates to platelet aggregation resisting medicinal composition which contains 100 weight portions of ticlopidine hydrochloride and 1.7 to 26 weight portions of nitrendipine, wherein the preferred content of nitrendipine is from 3 to 4 weight portions. The composition prepared according to the weight portions can be made into solid form unit doses. The medicinal composition has a favorable inhibiting effect on platelet aggregation. The medicinal composition is mainly used as an antithrombotic preparation, and is used in a disease occasion in which ticlopidine hydrochloride can be used. The synergistic effect of ticlopidine hydrochloride and nitrendipine can reduce the use doses of ticlopidine hydrochloride on the premise of ensuring or even improving therapeutic effects. The medicinal composition can also reduce the cost, and can lighten the burden of patients. The medicinal composition has favorable economical benefit and social benefit.
OBJECTIVES: Recurrent aphthous ulcer (RAU) is a prevalent oral mucosal disease, affecting around 20% of the global population. It can greatly impair the quality of life for affected individuals. However, the exact etiology of RAU remains unknown.
SUBJECTS AND METHODS: 16S rRNA sequencing (16S rRNA-seq) and non-targeted liquid chromatography-mass spectrometry (LC-MS) were employed to investigate the salivary microbiota and metabolic phenotype between RAU patients (N = 61) and healthy controls (HCs) (N = 105).
RESULTS: Findings from 16S rRNA -seq indicated reduced oral microbial diversity in RAU patients compared to HCs, but increased interactions. Clinical variables did not show any significant association with the overall diversity of oral microbiota in RAU patients. However, significant correlations were observed between specific microorganisms and clinical variables. LC-MS results revealed dysregulation of amino acid, lipid, nucleotide, and caffeine metabolism in RAU patients. Furthermore, correlation analysis of 16S rRNA-seq and LC-MS data revealed a significant association between salivary microbiota and metabolites in RAU patients.
CONCLUSIONS: Our study revealed notable differences in salivary microbiota and metabolic profiles between RAU patients and HCs, indicating a strong link between oral microbiota dysbiosis, metabolic disturbances, and the onset and progression of RAU.
<P>PROBLEM TO BE SOLVED: To provide a process and an apparatus by which a hydrogen-containing biocompatible solution to be used for injection, drip, infusion, organ preservation, etc. is easily produced.  <P>SOLUTION: A biocompatible solution enclosed in a container 2i such as an infusion (drip) bag having hydrogen permeability. The biocompatible solution together with the container is placed in another container 2g having a size large enough to accommodate it. A liquid or a gas containing hydrogen molecules (hereafter, hydrogen storage container) is fed to the container 2g. Hydrogen molecules are included in the biocompatible solution by bringing it in contact with hydrogen molecules from outside of the container.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Tuberculosis (TB) presents significant medical challenges, largely due to the genetic diversity of Mycobacterium tuberculosis, which enhances the resilience and resistance of the pathogen to first-line treatments. In response to the global rise of drug-resistant TB, second-line antitubercular drugs like bedaquiline (BDQ), linezolid (LZD), and clofazimine (CFZ) have become critical treatment options. Understanding the molecular changes these drugs induce is essential for optimizing TB therapy. To contribute to this effort, we investigated their impact on genome maintenance and stability using Mycobacterium smegmatis as a model organism. Using mutation accumulation assays and whole-genome sequencing, we found that the second-line antibiotics did not significantly increase mutation rates, unlike the positive control UV treatment. However, upon BDQ treatment, we detected mutations in transporter proteins and transcription factors without any increase in the minimal inhibitory concentration. Additionally, BDQ and CFZ were found to alter DNA repair pathways and reduce cellular dNTP levels, particularly CFZ, which depleted dGTP, impacting DNA synthesis. CFZ also upregulated DNA repair enzymes, enhancing error-free repairs. Despite minimal mutagenic effects, both drugs displayed distinct impacts on cellular mechanisms, suggesting additional modes of action.
SAD = single ascending dose. Each participant will receive a single dose of BMS-986196 or placebo.
In this cross-sectional study, it is planned to investigate the effects of 21st century skills on clinical decision making of nursing students. Junior and senior students of a nursing undergraduate program in Turkey will be recruited. The universe of the research consists of junior (167 people) and senior (210 people) nursing students of a nursing undergraduate program in a university in Turkey in the 2022-2023 academic year. Sample selection will not be made and those who volunteer to participate will be included. According to the university's nursing program curriculum, first and second year students were excluded from the study because they did not have clinical practice experience. Data will be collected using an Information Form containing sociodemographic data, Multidimensional 21st Century Skills Scale and Nursing Decision Making Instrument. Data collection forms will be collected on the online platform in line with the link created through Google forms. The link address will be shared via students' smartphones. After explaining to the students that the purpose of the study before the application, the participation is on a voluntary basis and the confidentiality of the information obtained will be ensured, they will be asked to fill in the online questionnaire by entering the address in the link. Data collection time is planned to take approximately 10-15 minutes. The dependent variable of the study was clinical decision making; independent variables are 21st century skills and sociodemographic characteristics. In this direction, data analysis will be based on the comparison of dependent and independent variables. If the data is continuous, it will be displayed as percentile, mean, standard deviation; comparison will be made by correlation analysis. Discrete data will be compared with dependent variable according to data level by t test or analysis of variance. The effect of 21st century skills and sociodemographic characteristics of nursing students on clinical decision making will be tested with multivariate regression analysis enter method. For categorical variables, a dummy model will be created and converted into continuous data. Statistical significance value will be accepted as p\<0.05.
TECVAYLI can cause serious or life-threatening neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) [see Adverse Reactions (6.1)] . 

In the clinical trial, neurologic toxicity occurred in 57% of patients who received TECVAYLI at the recommended dose, with Grade 3 or 4 neurologic toxicity occurring in 2.4% of patients. The most frequent neurologic toxicities were headache (25%), motor dysfunction (16%), sensory neuropathy (15%), and encephalopathy (13%).

With longer follow-up, Grade 4 seizure and fatal Guillain-Barré syndrome (one patient each) occurred in patients who received TECVAYLI.

In the clinical trial, ICANS was reported in 6% of patients who received TECVAYLI at the recommended dose [see Adverse Reactions (6.1)] . Recurrent ICANS occurred in 1.8% of patients. Most patients experienced ICANS following step-up dose 1 (1.2%), step-up dose 2 (0.6%), or the initial treatment dose (1.8%). Less than 3% of patients developed first occurrence of ICANS following subsequent doses of TECVAYLI. The median time to onset of ICANS was 4 (range: 2 to 8) days after the most recent dose with a median duration of 3 (range: 1 to 20) days. The most frequent clinical manifestations of ICANS reported were confusional state and dysgraphia. The onset of ICANS can be concurrent with CRS, following resolution of CRS, or in the absence of CRS. 

Monitor patients for signs and symptoms of neurologic toxicity during treatment. At the first sign of neurologic toxicity, including ICANS, immediately evaluate patient and provide supportive therapy based on severity. Withhold or permanently discontinue TECVAYLI based on severity per recommendations and consider further management per current practice guidelines [see Dosage and Administration (2.4)] . 

Due to the potential for neurologic toxicity, patients receiving TECVAYLI are at risk of depressed level of consciousness [see Adverse Reactions (6.1)] . Advise patients to refrain from driving or operating heavy or potentially dangerous machinery during and for 48 hours after completion of TECVAYLI step-up dosing schedule and in the event of new onset of any neurologic toxicity symptoms until neurologic toxicity resolves [see Dosage and Administration (2.1)] . 

TECVAYLI is available only through a restricted program under a REMS [see Warnings and Precautions (5.3)].
Intranasal administration, 24 IU oxytocin. Imaging starting 75min after nasal spray administration.